agreed. Keveyis nor the other AD Topicort spray drug has anything close to billion dollar.
Novexatin for sure (if clinical results are as promising as they touted after phase 2a) has potential to be a block buster
What is strange(could it be deliberate?) in this particular call, NOBODY even acknowledged that SUN strong performance is due to Taro(like it has been in past). If you look at the questions there was hardly any talk on Taro. Yet it was in significant part due to Taro, sun posted strong ebitda.
Maybe even the analyst community have been trained to be all "hush-hush" on TARO. Pls talk or ask abt ranbaxy & halol...
Not a single question was asked on the most important asset novexatin p2 even though it is expected that p2 topline data is known. Nobody asked this. While there were 10's of questions on Sun's Psoriasis asset. Sun has been very vocal to analyst community in answering questions on tildrakizumab. Some find this hypocritical. Why not talk about Novexatin ? It is after all a highly differentiated product likely to cannibalize $6b a year market, of course if p3 results are successful. Why not even make a statement like "we will disclose p2 results in the future xx/xx/2016...."
THE TRUTH IS IN NUMBERS. TARO is still significant part of Sun-Ranbaxy consolidated ebitda. Thanks Larry for pointing. The numbers don't lie. No matter what spin you try to give.
Despite ranbaxy consolidation TARO is huge profits are hugely and positively impacting sun
Put that $1.2 b cash to use!
Listens partly and they said sun is not looking to acquire...just consolidate...
Wonder what that means for TARO. I guess I still believe kals words that TARO is looking and is ready to take on debt if required.
Blackrock has taken about 150K new position
Mathew has marginally reduced but still over 500K
Still no filings from key holders
6. Last but not least FMR
I guess cash is likely going to be used as a bait to woo some tired
Value investor in me tells its a good move. However going by past karma I think it's a bad move for minorty
excellent results as usual. but look at the F stock price . imo it should be around $250-$300 for a business that has CONSISTENTLY (5 years and counting) posted strong results and the precedent transaction multiples in the nichge generic business like gavis pharma, strides and the super-super-pristine balance sheet that will allow them to buy assets now.
Ackman loves the debt-ridden and totally unproven(num are all thru acquisitions) VRX and buy taro man.
Yes, but there will be some distressed selling .....companies needing cash to operate .
Regarding your last statement you are better off asking that to taros chairman. maybe he can explain how he will be loyal to all shareholders of taro, when it comes to using 4 years of cash hoard and how the benefits of this 4 year cash hoard will inure to ALL of taro's shareholders
my understanding is topicort is already used off-label for AD. I understand the company can't market it to dermatologists now. my question is will getting it on-label make a big diff ? what could be the $ potential
i guess they will get some years of FDA data exclusivity 3? 5-8 years?
If u suspect wrongdoing why don't you take action or at least write an open letter to the chairman or board and tell them that this is not right or fair ????!?
Wow you seem to be alleging something serious. Why would you write an Open letter to the board expressing your facts and opinions ? As far as I know u have been holding shares for a long time.
Personally I am all for 2 way communications bw shareholders and their business partners/reps on the board. This lack of communication (2way) needs to be reformed...it is directly bcoz of lack of solid and frequent interactions bw shareholders and their business partners on board, lhere is less transparency, accountability, . personally I would be interested to see your viewpoints on what needs to be done here by our business partners
For example I loathe the lack of info sharing on dsxs, nvxt & other highly. Significant value adding projects.....
Consistent with the Company’s policy, Taro will conduct its next earnings call when it announces its financial results for the year-ending March 31, 2016.
You would think this would have been an opportune time to update business partners (public shareholders) on dsxs and nvxt ? How do your business partners perceive ? Does this really promote trust and goodwill and give good karma ?